Clinical Cancer Research · 2013 · 136 citations · 30 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyCancer Cell SignalingEpithelial-mesenchymal TransitionLung Cancer PharmacotherapyMolecular Tumor ProfilingTargeted Cancer TherapyTargeted TherapyEpithelial-mesenchymal Transition In CancerEpithelial-mesenchymal Transition MarkersHepatocyte Growth Factor Receptor SignalingHepatocyte Growth Factor SignalingMet InhibitorsMet-targeted TherapyPatient Outcome EvaluationSmall Cell Lung Cancer Therapy
PURPOSE: Met receptor phosphorylation is associated with poor prognosis in human small cell lung cancer (SCLC). The aim of our work was to investigate the effects of hepatocyte growth factor (HGF)/Met-mediated epithelial-to-mesenchymal transition (EMT) in SCLC and to evaluate the role of Met inhibition in mesenchymal/chemorefractory SCLC models. EXPERIMENTAL DESIGN: SCLC models of HGF-induced EMT were evaluated in vitro and in vivo (subcutaneous xenografts in BALB/c nude mice) for chemosensitivity and response to Met inhibition with PF-2341066 (crizotinib). Human SCLC samples at diagnosis (N = 87) and relapse (N = 5) were evaluated by immunohistochemistry and immunofluorescence for EMT markers and Met status and these were correlated with patient outcome. RESULTS: We identified that the activation of the Met receptor through HGF induced expression of mesenchymal markers, an aggressive phenotype, and chemoresistance. Blockade of this process with the Met inhibitor resensitized cells to chemotherapy in vitro and in vivo. Moreover, mesenchymal markers in human SCLC specimens were associated with Met activation, predicted worse survival, and were upregulated in chemorefractory disease. CONCLUSION: These results provide novel evidence on an important role of Met-dependent EMT in the adverse clinical behavior of SCLC and support clinical trials of Met inhibitors and chemotherapy in this fatal disease.
30
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · New England Journal of Medicine · 2009 · 8.2K citations · Full text
Medicine, Oncology, Pharmacology +13
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge et al. · New England Journal of Medicine · 2010 · 4.5K citations
Medicine, Oncology, Pharmacology +14
Direct regulation of TWIST by HIF-1α promotes metastasis
Muh Hwa Yang, Min-Zu Wu, Shih Hwa Chiou et al. · Nature Cell Biology · 2008 · 1.3K citations
A small-cell lung cancer genome with complex signatures of tobacco exposure
Erin Pleasance, Philip J. Stephens, Sarah O’Meara et al. · Nature · 2009 · 1.1K citations · Full text
Life Sciences, Genetics, Oncology +17